George: I think the fear is, like you said, people see this name banded a bit. Maybe a bit too much. It's always shown as like your swan sleep well at night stock. And it might not get the due diligence that it probably deserves. They're spinning off the consumer health and are going completely into the biotech world. But in saying that, they are a dividend king and a triple A rated company for a reason as well. George: Long term, I think these guys could be a good bet, really bullish on that whole sector of America.